
Sue Bird taking on new career challenge with USA Basketball ‘puzzle'
For years, Sue Bird called the shots on the court as a point guard. Now, the legendary WNBA star will be doing it off the court for USA Basketball.
On Thursday, Bird was appointed USA Basketball's first managing director for the women's national team.
For years, the women's national team roster and coaching staff had been selected by a committee.
But that will change moving forward as Bird will lead those decisions, starting with next year's World Cup in Berlin.
'I know what I bring, I know what my perspective gives, and I know what my experience can provide, and there's also things that I need to learn,' Bird said during a press conference at Nike NYC Headquarters in Manhattan. 'There's also things I want to talk to other people, pick brains, maybe ask people what their experiences have been like, so that combination will probably be my next however many months.'
Bird, a five-time Olympic champion, wasn't initially interested in the opportunity when USA Basketball first approached her about it shortly after she retired from playing in 2022.
6 WNBA legend Sue Bird in attendance for the New York Liberty vs the Atlanta Dream during Round 1 Game 1 of the 2024 WNBA playoffs at Barclays Center.
Michelle Farsi/New York Post
6 Seattle Storm's Sue Bird in action against the Los Angeles Sparks in a WNBA basketball game Saturday, June 6, 2015.
AP
Grant Hill, who held the position on the men's side from 2021 to 2024, has been recruiting Bird to join USA Basketball as an executive for some time now.
His efforts got to the point where Bird called him an 'annoying older brother.'
But as time passed, Bird opened up to the idea.
'The exact amount of months, years, when they first brought this up is a little blurry, but I hadn't been retired that long, and I still very much felt like a player,' Bird said. 'I hadn't really made that adjustment in my mind. So the idea of picking a team, I was like, 'What? I don't want any part of that.' So I think just time naturally did that, but also talking to Grant really played a big role in just making me see things in a different way.'
Liberty star Breanna Stewart, who played alongside Bird for several seasons in Seattle, believes she's a perfect fit for this role.
'Not only has she played [and] she has the player perspective, but she's watching all the time,' Stewart said after practice. 'She knows the best pieces to kind of put the puzzle together, and I'm happy for her and happy that I'll be able to work alongside her.'
6 Sue Bird speaks on stage during the 'A Touch More' live podcast at the 2025 SXSW Conference and Festival Austin Convention Center on March 09, 2025 in Austin, Texas.
Getty Images
6 Breanna Stewart #30 of the New York Liberty laughs with Sue Bird after the game against the Seattle Storm on May 20, 2024 at Barclays Center in Brooklyn, New York.
NBAE via Getty Images
Stewart said she once again wants to suit up for Team USA in next year's World Cup. She also has her eyes set on the 2028 Summer Games in Los Angeles.
Bird is assuming the managing director role at a time when there's plenty of young star power in the pipeline.
She said she's open to integrate Caitlin Clark and Paige Bueckers into the women's national team pool ahead of the 2028 Olympics.
6 Caitlin Clark (22) returned to Carver-Hawkeye Arena in Iowa City for a WNBA preseason game against the Brazil national team on May 4, 2025.
Grace Smith / USA TODAY NETWORK via Imagn Images
6 Paige Bueckers (5) sits to speak to reporter during a WNBA basketball media day in Arlington, Texas, Wednesday, May 7, 2025.
AP
'Any player that is interested in being part of the national team, of course, is welcome,' Bird said. 'You just want talent and you want to see which talent when they come together is going to fit. Of course, Caitlin. Of course, Paige. I mean, the names go on — you want them to be involved as quickly as possible to get comfortable.
'USA Basketball, from a player standpoint, can be an uncomfortable situation because we don't have a lot of training time and you're asked to do possibly, potentially, a different role, and you're trying to do that on the fly.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio


Washington Post
22 minutes ago
- Washington Post
Cars set on fire as L.A. protests continue
RFK Jr. has big plans for your food. Here are the facts. May 2, 2025
Yahoo
30 minutes ago
- Yahoo
Sky guard Courtney Vandersloot tears ACL, will miss rest of 2025 season
Chicago Sky guard Courtney Vandersloot will miss the remainder of the 2025 WNBA season after suffering a torn ACL in her right knee during Chicago's eventual 27-point loss to the Indiana Fever, the team announced Sunday. Vandersloot sustained the injury at the 5:29 mark of the first quarter of Saturday night's loss to Indiana while driving to the basket. Teammates gathered around her on the court as she lay on the floor in pain, and Vandersloot was eventually carried to the locker room before quickly being ruled out for the remainder of the contest. Advertisement 'It's heartbreaking,' Sky rookie guard Hailey Van Lith said after Chicago's loss. 'She's our engine,' coach Tyler Marsh added. 'She's our captain and our leader out there, so obviously, it's a huge blow.' Angel Reese, the second-year forward from LSU, posted her reaction on X. Vandersloot, 36, was the No. 3 pick of the Sky in 2011 and spent the first 12 years of her career with the franchise, leading Chicago to its first championship in 2021. She played the 2023 and 2024 seasons with the New York Liberty, where she won the 2024 title, before returning to the Sky on a one-year deal this past offseason. Advertisement 'We're thinking of her,' Liberty coach Sandy Brondello told reporters on Sunday. 'She's playing great. She's the leader out there.' Heading into this season, Vandersloot had already been Chicago's all-time assists leader, and she became the franchise's all-time leading scorer in late May, passing her wife, and fellow former Sky guard, Allie Quigley on the Sky's scoring list. Vandersloot started the first seven games of Chicago's season, averaging 10.6 points and 5.3 assists. Her injury will likely thrust Van Lith, the No. 11 pick in April's draft, into the Sky's starting lineup. Van Lith replaced Vandersloot after the injury occurred and played a career-high 26 minutes in Saturday's loss, which was the first WNBA game at the United Center. The Sky will also likely lean more on guards Ariel Atkins and Rachel Banham as they look to proceed and draw the most out of their developing frontcourt of Kamilla Cardoso and Angel Reese. Advertisement Their first test without Vandersloot comes Tuesday, against her former team, as the Sky travel to Brooklyn to play the Liberty. This article originally appeared in The Athletic. Chicago Sky, WNBA 2025 The Athletic Media Company